COPN — Cosmo Pharmaceuticals NV Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapContrarian

Annual balance sheet for Cosmo Pharmaceuticals NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Short Term Investments
Cash and Short Term Investments	213	222	241	50.3	143
Net Total Accounts Receivable
Net Total Receivables	31.6	38.6	50.6	34.4	30.6
Total Inventory
Prepaid Expenses
Total Current Assets	253	276	306	102	202
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	29.3	30.5	30.3	28.6	29.1
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	596	806	760	526	647
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	21.8	21.2	195	25.1	48.3
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Liabilities	196	300	303	129	148
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Unrealized Gain / Loss
Other Equity
Total Equity	400	505	457	397	498
Total Liabilities & Shareholders' Equity	596	806	760	526	647
Total Common Shares Outstanding